| Literature DB >> 27989629 |
Chloé Rancoule1, Jean-Baptiste Guy1, Alexis Vallard2, Majed Ben Mrad2, Amel Rehailia2, Nicolas Magné3.
Abstract
We have just celebrated the 50th anniversary of cisplatin cytotoxic potential discovery. It is time to take stock… and it seems mainly positive. This drug, that revolutionized the treatment of many cancer types, continues to be the most widely prescribed chemotherapy. Despite significant toxicities, resistance mechanisms associated with treatment failures, and unresolved questions about its mechanism of action, the use of this cytotoxic agent remains unwavering. The interest concerning this "old" invincible drug has not yet abated. Indeed many research axes are in the news. New platinum salts agents are tested, new cisplatin formulations are developed to target tumor cells more efficiently, and new combinations are established to increase the cytotoxic potency of cisplatin or overcome the resistance mechanisms.Entities:
Keywords: Carboplatin; Carboplatine; Chemotherapy; Chimiothérapie; Cisplatin; Cisplatine; Oxaliplatin; Oxaliplatine; Resistance; Résistances; Toxicities; Toxicités
Mesh:
Substances:
Year: 2016 PMID: 27989629 DOI: 10.1016/j.bulcan.2016.11.011
Source DB: PubMed Journal: Bull Cancer ISSN: 0007-4551 Impact factor: 1.276